Optimizing adjuvants for intradermal delivery of MenC glycoconjugate vaccine

Highlights • Novel strategy to develop intradermally administered MenC glycoconjugate vaccine. • New glycoconjugate formulation was developed using a robust, scalable process. • Intradermal administration of MenC glycoconjugate vaccine is beneficial. • Appropriate adjuvants direct immune response to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2017-07, Vol.35 (32), p.3930-3937
Hauptverfasser:	Donadei, Agnese, Balocchi, Cristiana, Romano, Maria R, Panza, Luigi, Adamo, Roberto, Berti, Francesco, O'Hagan, Derek T, Gallorini, Simona, Baudner, Barbara C
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants Adjuvants, Immunologic - administration & dosage Allergy and Immunology Aluminum Animals Antigen-presenting cells Antigens Bacterial Toxins - administration & dosage Chromatography Dendritic cells Development strategies Drug delivery systems E coli Enterotoxins - administration & dosage Escherichia coli Proteins - administration & dosage Female Galactosylceramide Galactosylceramides - administration & dosage Glycoconjugate vaccines Heat-labile enterotoxin Hypodermic needles Immune response Immune system Immunogenicity Influenza Injection Injections, Intradermal Intradermal Ligands Lymphocytes T Meningococcal Vaccines - administration & dosage Meningococcal Vaccines - immunology Mice, Inbred BALB C Needles Neisseria MenC Oils - administration & dosage Proteins Skeletal muscle Skin Software T cell receptors Toll-like receptors Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Novel strategy to develop intradermally administered MenC glycoconjugate vaccine. • New glycoconjugate formulation was developed using a robust, scalable process. • Intradermal administration of MenC glycoconjugate vaccine is beneficial. • Appropriate adjuvants direct immune response to a more effective quality profile.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2017.06.018